Reimbursing Rare Disease Drugs: Getting Away From High Co-Pays
This article was originally published in RPM Report
Former CMS Administrator Mark McClellan argues that drugs for rare disease should not be on the high-cost-sharing specialty tier of Medicare Part D formularies. “High value” therapies deserve low co-pays, he argues.
You may also be interested in...
Two former biotech high flyers are up for sale, with Amylin attracting more would-be suitors than Human Genome Sciences. The spectacle of the bidding is great. But did you know that the orphan drug company Alexion is worth more than those two companies combined?
With the recent addition of claims data from two major insurance companies, the FDA postmarketing drug safety surveillance pilot project known as Mini Sentinel has already exceeded its statutory goal of gaining access to electronic health care data for 100 million individuals by July 12, 2012.
Tim Coté has been a tireless advocate for greater involvement by Big Pharma in orphan drug research since taking over as head of FDA's Orphan Products Office two years ago. We talked to him about the response he's heard so far.